Quốc gia: Canada
Ngôn ngữ: Tiếng Anh
Nguồn: Health Canada
VASOPRESSIN
FRESENIUS KABI CANADA LTD
H01BA01
VASOPRESSIN (ARGIPRESSIN)
20UNIT
SOLUTION
VASOPRESSIN 20UNIT
INTRAMUSCULAR
1ML
Prescription
PITUITARY
Active ingredient group (AIG) number: 0106469001; AHFS:
APPROVED
1998-07-02
Prescribing Information - Vasopressin Injection, USP Page 1 of 9_ _ PRESCRIBING INFORMATION PR VASOPRESSIN INJECTION, USP Vasopressin Injection Sterile Solution 20 USP units / mL Synthetic For Intramuscular (IM) or Subcutaneous (SC) Injection Antidiuretic Agent Fresenius Kabi Canada Ltd. 165 Galaxy Blvd, Suite 100 Toronto, ON M9W 0C8 Date of Initial Authorization: OCT 03, 1994 Date of Revision: MAR 28, 2022 Submission Control Number: 255357 Prescribing Information - Vasopressin Injection, USP Page 2 of 9_ _ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 03/2022 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 03/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ..................................................................................................2 TABLE OF CONTENTS ..................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .............................................................................4 1 INDICATIONS ..................................................................................................................4 1.1 Pediatrics............................................................................................................. 4 1.2 Geriatrics ............................................................................................................. 4 2 CONTRAINDICATIONS......................................................................................................4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ....................................................................4 4 DOSAGE AND ADMINISTRATION .......................................................................................5 4.1 Dosing Considerations ........................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment ............................................... Đọc toàn bộ tài liệu